Alzheimer's Disease: From Pathology to Therapeutic Approaches

Cites (314)

Items 201–312 of 312

1. Alzheimer disease γ-secretase: a complex story of GxGD-type presenilin proteases
   Christian Haass, Harald Steiner · 2002 · Trends in Cell Biology
2. Intramembrane proteolysis by presenilins
   Steiner, Harald, Haass, Christian · 2000 · Nature Reviews Molecular Cell Biology
3. Three weeks of running wheel exposure improves cognitive performance in the aged Tg2576 mouse
   Kathryn E. Nichol, Anna I. Parachikova, Carl W. Cotman · 2007 · Behavioural Brain Research
4. Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor
   Barten, D.M., Guss, V.L., Corsa, J.A., Loo, A., Hansel, S.B., Zheng, M., Munoz, B., Srinivasan, K., Wang, B., Robertson, B.J. et al. · 2005 · The Journal of Pharmacology and Experimental Therapeutics
5. Episodic memory impairment in patients with Alzheimer’s disease is correlated with entorhinal cortex atrophy
   M. Paola, Emiliano Macaluso, Giovanni Augusto Carlesimo, Francesco Tomaiuolo, Keith J. Worsley, Lucia Fadda, Carlo Caltagirone · 2007 · Journal of Neurology
6. Synaptic memory mechanisms: Alzheimer's disease amyloid β-peptide-induced dysfunction
   Michael J. Rowan, Igor V. Klyubin, Qingyong Wang, Neng‐Wei Hu, Roger Anwyl · 2007 · Biochemical Society Transactions
7. Alzheimer's Disease: A Lesson from Mitochondrial Dysfunction
   Paula Isabel Moreira, Maria S. Santos, Catarina Resende Oliveira · 2007 · Antioxidants and Redox Signaling
8. Presenilin diversifies its portfolio
   Annette L. Parks, Daniel Curtis · 2007 · Trends in Genetics
9. Profound Amnesia After Damage to the Medial Temporal Lobe: A Neuroanatomical and Neuropsychological Profile of Patient E. P.
   Stefanacci, Lisa, Buffalo, Elizabeth A., Schmolck, Heike, Squire, Larry R. · 2000 · The Journal of Neuroscience
10. βA4 deposits are constant in the brain of the oldest old: An immunocytochemical study of 20 french centenarians
    Delaère, Pia, He, Yi, Fayet, Guillemette, Duyckaerts, Charles, Hauw, Jean-Jacqes · 1993 · Neurobiology of Aging
11. Amyloid β Binds Trimers as Well as Monomers of the 75-kDa Neurotrophin Receptor and Activates Receptor Signaling
    Mina Yaar, Sen Zhai, Richard E. Fine, Patricia B. Eisenhauer, Bennett L. Arble, Kenneth B. Stewart, Barbara A. Gilchrest · 2002 · Journal of Biological Chemistry
12. The crystal structure of the rhomboid peptidase from <i>Haemophilus influenzae</i> provides insight into intramembrane proteolysis
    Lemieux, M. Joanne, Fischer, Sarah J., Cherney, Maia M., Bateman, Katherine S., James, Michael N. G. · 2007 · Proceedings of the National Academy of Sciences
13. The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice
    Thomas A. Lanz, Carol S. Himes, Giovanni Pallante, Lisa Adams, Shinji Yamazaki, Ben Amore, Kalpana Merchant · 2003 · Journal of Pharmacology and Experimental Therapeutics
14. Treatment with an Amyloid-β Antibody Ameliorates Plaque Load, Learning Deficits, and Hippocampal Long-Term Potentiation in a Mouse Model of Alzheimer's Disease
    Hartman, Richard E., Izumi, Yukitoshi, Bales, Kelly R., Paul, Steven M., Wozniak, David F., Holtzman, David M. · 2005 · The Journal of Neuroscience
15. Transgenic mouse models of Alzheimer's disease: phenotype and application.
    2003 · PubMed
16. Paradoxical Upregulation of Glutamatergic Presynaptic Boutons during Mild Cognitive Impairment
    Karen F. S. Bell, David Alan Bennett, A. Claudio Cuello · 2007 · Journal of Neuroscience
17. Autophagocytosis of Mitochondria Is Prominent in Alzheimer Disease
    Paula Isabel Moreira, Sandra L. Siedlak, Xinglong Wang, Maria S. Santos, Catarina Resende Oliveira, Massimo Tabaton, Akihiko Nunomura, Luke I. Szweda, Gjumrakch M. Aliev, Mark A. Smith et al. · 2007 · Journal of Neuropathology & Experimental Neurology
18. Oxidative Metabolites Accelerate Alzheimer's Amyloidogenesis by a Two-Step Mechanism, Eliminating the Requirement for Nucleation
    Jan Bieschke, Qinghai Zhang, Evan T. Powers, Richard Alan Lerner, Jeffery W. Kelly · 2005 · Biochemistry
19. Current and future uses of neuroimaging for cognitively impaired patients
    Gary W. Small, Susan Y. Bookheimer, Paul M. Thompson, Greg M. Cole, S-C Huang, Vladimir Kepe, Jorge R. Barrio · 2008 · The Lancet Neurology
20. Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-&bgr; After Inhibition of &ggr;-Secretase
    E. Siemers, R. Dean, S. Friedrich, Lisa Ferguson-Sells, C. Gonzales, M. Farlow, P. May · 2007 · Clinical Neuropharmacology
21. Amyloid-β in Alzheimer Disease: The Null versus the Alternate Hypotheses
    Hyoung‐gon Lee, Xiongwei Zhu, Rudy J. Castellani, Akihiko Nunomura, George L. Perry, Mark A. Smith · 2007 · Journal of Pharmacology and Experimental Therapeutics
22. Neurofibrillary Pathology—Correlation With Hippocampal Formation Atrophy in Alzheimer Disease
    Maciej Bobinski, Jerzy Węgiel, Henryk M. Wı́sniewski, Michal J Tarnawski, Margaret Bobinski, ‌Barry Reisberg, Mony J. de Leon, Douglas Craig Miller · 1996 · Neurobiology of Aging
23. Complement Component C1q Modulates the Phagocytosis of Aβ by Microglia
    Webster, Scott D., Yang, Austin J., Margol, Larry, Garzon-Rodriguez, William, Glabe, Charles G., Tenner, Andrea J. · 2000 · Experimental Neurology
24. Senile plaque composition and posttranslational modification of amyloid-β peptide and associated proteins
    Craig Atwood, Ralph Nigel Martins, Mark A. Smith, George L. Perry · 2002 · Peptides
25. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: New cues into the human disease?
    Eva Carro, José Luís Trejo, Carlos Spuch, Delphine Bohl, Jean Michel Heard, Ignacio Torres‐Alemán · 2005 · Neurobiology of Aging
26. Direct Observation of Amyloid Fibril Growth, Propagation, and Adaptation
    Tadato Ban, Kei‐ichi Yamaguchi, Yuji Goto · 2006 · Accounts of Chemical Research
27. The Experimental Alzheimer’s Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice
    Debomoy K. Lahiri, De‐Mao Chen, Bryan Maloney, Harold W. Holloway, Qian-sheng Yu, Tada Utsuki, Tony Giordano, Kumar Sambamurti, Nigel H. Greig · 2006 · Journal of Pharmacology and Experimental Therapeutics
28. Current progress in beta-amyloid immunotherapy
    Dale Schenk, Michael Hagen, Peter A. Seubert · 2004 · Current Opinion in Immunology
29. Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential
    Michael S. Wolfe · 2001 · Journal of Medicinal Chemistry
30. γ-Cleavage Is Dependent on ζ-Cleavage during the Proteolytic Processing of Amyloid Precursor Protein within Its Transmembrane Domain
    Guojun Zhao, Mei‐Zhen Cui, Guozhang Mao, Yunzhou Dong, Jianxin Tan, Longsheng Sun, Xuemin Xu · 2005 · Journal of Biological Chemistry
31. Concentration-Dependent Modulation of Amyloid-β in Vivo and in Vitro Using the γ-Secretase Inhibitor, LY-450139
    Thomas A. Lanz, Michael J. Karmilowicz, Kathleen M. Wood, Nikolay Pozdnyakov, Ping Du, Mary A. Piotrowski, Tracy M. Brown, Charles E. Nolan, Karl E. G. Richter, James E. Finley et al. · 2006 · Journal of Pharmacology and Experimental Therapeutics
32. Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
    Alejandra del C. Alonso, Ben Li, Inge Grundke, Khalid Iqbal · 2008 · Current Alzheimer Research
33. Mitochondria in Alzheimer's disease
    Swerdlow, Russell H., Kish, Stephen J. · 2002 · International review of neurobiology
34. Alzheimer 100 – highlights in the history of Alzheimer research
    K. A. Jellinger · 2006 · Journal of Neural Transmission
35. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?
    Sascha Weggen, Mark V. Rogers, Jason L. Eriksen · 2007 · Trends in Pharmacological Sciences
36. Amyloid β plaque-associated proteins C1q and SAP enhance the Aβ1–42 peptide-induced cytokine secretion by adult human microglia in vitro
    Veerhuis, Robert, Van Breemen, Mariëlle J., Hoozemans, Jeroen J., Morbin, Michela, Ouladhadj, Jamal, Tagliavini, Fabrizio, Eikelenboom, Piet · 2003 · Acta Neuropathologica
37. Substrate Activation of Insulin-degrading Enzyme (Insulysin)
    Eun-Suk Song, María A. Juliano, Luiz Juliano, Louis B. Hersh · 2003 · Journal of Biological Chemistry
38. Role of ERAB/l-3-Hydroxyacyl-coenzyme A Dehydrogenase Type II Activity in Aβ-induced Cytotoxicity
    Shi Du Yan, Yigong Shi, Aiping Zhu, Jin Fu, Huaijie Zhu, Yucui Zhu, Lenneen Gibson, Eric Stern, Kate S. Collison, Futwan A Al-Mohanna et al. · 1999 · Journal of Biological Chemistry
39. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid β‐peptide
    Townsend, Kirk P., Town, Terrence, Mori, Takashi, Lue, Lih‐Fen, Shytle, Doug, Sanberg, Paul R., Morgan, David, Fernandez, Francisco, Flavell, Richard A., Tan, Jun · 2005 · European Journal of Immunology
40. Alpha-Secretase As a Therapeutic Target
    Falk Fahrenholz · 2007 · Current Alzheimer Research
41. Alzheimer’s Disease and the Cerebellum: A Morphologic Study on Neuronal and Glial Changes
    Martin Sjöbeck, Elisabet M. Englund · 2001 · Dementia and Geriatric Cognitive Disorders
42. Magnetization Transfer Ratio in Mild Cognitive Impairment and Dementia of Alzheimer's Type
    Noor Jehan Kabani, John G. Sled, Howard Mark Chertkow · 2002 · NeuroImage
43. Biomarkers of Alzheimer Disease
    John H. Growdon · 1999 · Archives of Neurology
44. Signal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease
    Robert B. Petersen, Akihiko Nunomura, Hyoung‐gon Lee, Gemma Casadesús, George L. Perry, Mark A. Smith, Xiongwei Zhu · 2007 · Journal of Alzheimer s Disease
45. Amyloid Angiopathy and Blood–Brain Barrier Changes in Alzheimer's Disease a, b
    Henryk M. Wı́sniewski, ANDRZEJ W. VORBRODT, JERZY WEGIEL · 1997 · Annals of the New York Academy of Sciences
46. Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor γ Agonist Treatment
    Christian Grommes, Gary E. Landreth, Magdalena Sastre, Martina Beck, Douglas L. Feinstein, Andreas H. Jacobs, Uwe S. Schlegel, Michael Thomas Heneka · 2006 · Molecular Pharmacology
47. Calpain : pharmacology and toxicology of calcium-dependent protease
    Kevin Wang, Po‐wai Yuen · 1999 · Taylor & Francis eBooks
48. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease—a neuropathological study
    Martin Sjöbeck, Mattias Haglund, Elisabet M. Englund · 2005 · International Journal of Geriatric Psychiatry
49. Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ-Secretase Inhibitor LY-411575 [N2-[(2 S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H-dibenzo[b,d]azepin-7-yl]-l-alaninamide]
    Jonathan D. Best, Mark T. Jay, Franklin Otu, Jerome Ma, Alan J. Nadin, Semantha Ellis, Huw D. Lewis, Christine Pattison, Michael Reilly, Timothy Harrison et al. · 2005 · Journal of Pharmacology and Experimental Therapeutics
50. Fast anterograde transport of Herpes Simplex Virus: Role for the amyloid precursor protein of Alzheimer's disease
    Prasanna Satpute‐Krishnan, Joseph A. DeGiorgis, Elaine L. Bearer · 2003 · Aging Cell
51. The Solved and Unsolved Mysteries of the Genetics of Early-Onset Alzheimer 's Disease
    Ekaterina A. Rogaeva · 2002 · NeuroMolecular Medicine
52. Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs
    Bruno Martoglio, Todd Eliot Golde · 2003 · Human Molecular Genetics
53. Neuroimaging and APOE Genotype: A Systematic Qualitative Review
    Nicolas Cherbuin, Liana Leach, Helen M Christensen, Kaarin Jane Anstey · 2007 · Dementia and Geriatric Cognitive Disorders
54. Mice as models: Transgenic approaches and Alzheimer's disease
    Dora Games, Manuel Buttini, Dione T. Kobayashi, Dale Schenk, Peter A. Seubert · 2006 · Journal of Alzheimer s Disease
55. Amyloid β Protein (Aβ) Starts to Deposit As Plasma Membrane-Bound Form in Diffuse Plaques of Brains from Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch Type, Alzheimer Disease and Nondemented Aged Subjects
    Haruyasu Yamaguchi, Marion L. C. Maat–Schieman, Sjoerd G. van Duinen, Frans A. Prins, Peter Neeskens, Remco Natté, Raymund A.C. Roos · 2000 · Journal of Neuropathology & Experimental Neurology
56. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders
    Raj N. Kalaria, Pamela G. Galloway, George L. Perry · 1991 · Neuropathology and Applied Neurobiology
57. The β‐amyloid protein of Alzheimer’s disease binds to membrane lipids but does not bind to the α7 nicotinic acetylcholine receptor
    David Henry Small, Danuta Maksel, Megan L. Kerr, Judy Ng, Xu Hou, Cindy Chu, Hossein Ali Mehrani, Sharon E. Unabia, Michael F. Azari, Richard E. Loiacono et al. · 2007 · Journal of Neurochemistry
58. Cholesterol, statins and dementia
    Benjamin L. Wolozin · 2004 · Current Opinion in Lipidology
59. Amyloid at the cutting edge: activation of α-secretase prevents amyloidogenesis in an Alzheimer disease mouse model
    Stefan F. Lichtenthaler, Christian Haass · 2004 · Journal of Clinical Investigation
60. Ganglioside GM1-Mediated Amyloid-beta Fibrillogenesis and Membrane Disruption
    Eva Y. Chi, Shelli L. Frey, Ka Yee C. Lee · 2007 · Biochemistry
61. Apolipoprotein E, a Gene with Complex Biological Interactions in the Aging Brain
    Allen D. Roses · 1997 · Neurobiology of Disease
62. Use of structural imaging to study the progression of Alzheimer's disease
    A. David Smith, K. A Jobst · 1996 · British Medical Bulletin
63. Apoptosis in Alzheimer Disease: A Mathematical Improbability
    Xiongwei Zhu, Arun K. Raina, George L. Perry, Mark A. Smith · 2006 · Current Alzheimer Research
64. The modulation of metal bio‐availability as a therapeutic strategy for the treatment of Alzheimer's disease
    P. Crouch, A. White, A. I. Bush · 2007 · The FEBS Journal
65. 4-Substituted cyclohexyl sulfones as potent, orally active γ-secretase inhibitors
    Ian Churcher, Dirk Beher, Jonathan D. Best, José L. Castro, Earl E. Clarke, Amy L. Gentry, Timothy Harrison, Laure Hitzel, Euan R. Kay, Sonia Kerrad et al. · 2005 · Bioorganic & Medicinal Chemistry Letters
66. The genetics of neurodegenerative diseases
    John Hardy, Harry T. Orr · 2006 · Journal of Neurochemistry
67. Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of β-amyloid protein
    Haruhiko Akiyama, Claudia Schwab, Hiromi Kondo, Hiroshi Mori, Fuyuki Kametani, Kenji Ikeda, Patrick L. McGeer · 1996 · Neuroscience Letters
68. α‐Secretase Activity of the Disintegrin Metalloprotease ADAM 10: Influences of Domain Structure
    Falk Fahrenholz, SANDRA GILBERT, Elżbieta Kojro, Sven Lammich, Rolf Postina · 2000 · Annals of the New York Academy of Sciences
69. Mutations in APP have independent effects on Aβ and CTFγ generation
    Hecimovic, Silva, Wang, Jun, Dolios, Georgia, Martinez, Maribel, Wang, Rong, Goate, Alison M. · 2004 · Neurobiology of Disease
70. Molecular genetics of Alzheimer’s disease
    Pau Pástor, Alison Goate · 2004 · Current Psychiatry Reports
71. Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants
    Quan Liu, Fang Xie, Raj K. Rolston, Paula Isabel Moreira, Akihiko Nunomura, Xiongwei Zhu, Mark A. Smith, George L. Perry · 2007 · Mini-Reviews in Medicinal Chemistry
72. The Failure in NGF Maturation and its Increased Degradation as the Probable Cause for the Vulnerability of Cholinergic Neurons in Alzheimer’s Disease
    A. Claudio Cuello, Martin Alejandro Bruno · 2007 · Neurochemical Research
73. Intracellular oxidation of allopregnanolone by human brain type 10 17beta-hydroxysteroid dehydrogenase
    Xue‐Ying He, Jerzy Węgiel, Song‐Yu Yang · 2005 · Brain Research
74. In Vivo Characterization of Aβ(40) Changes in Brain and Cerebrospinal Fluid Using the Novel γ-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the Rat
    Jonathan D. Best, Mark T. Jay, Franklin Otu, Ian Churcher, Michael Reilly, Pablo Morentin Gutierrez, Christine Pattison, Tim Harrison, Mark S. Shearman, John R. Atack · 2006 · Journal of Pharmacology and Experimental Therapeutics
75. Application of Automated Medial Temporal Lobe Atrophy Scale to Alzheimer Disease
    Basil H. Ridha, Josephine Barnes, Laura A. van de Pol, Jonathan M. Schott, Richard G. Boyes, Musib M. Siddique, Martin N. Rossor, Philip Scheltens, Nick C. Fox · 2007 · Archives of Neurology
76. Amyloid Associated Proteins in Alzheimers and Prion Disease
    Robert Veerhuis, Ronald S. Boshuizen, Atoosa Familian · 2005 · CNS & Neurological Disorders - Drug Targets
77. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease
    Dirk Beher, Samuel Lindsay Graham · 2005 · Expert Opinion on Investigational Drugs
78. Trafficking of Alzheimer's Disease–Related Membrane Proteins and Its Participation in Disease Pathogenesis
    Toshiharu Suzuki, Yoichi Araki, Tohru Yamamoto, Tadashi Nakaya · 2006 · The Journal of Biochemistry
79. β-Galactoside α2,6-Sialyltransferase I Cleavage by BACE1 Enhances the Sialylation of Soluble Glycoproteins
    Ichiro Sugimoto, Satoshi Futakawa, Ritsuko Oka, Kazuko Ogawa, Jamey D. Marth, Eiji Miyoshi, Naoyuki Taniguchi, Yasuhiro Hashimoto, Shinobu Kitazume · 2007 · Journal of Biological Chemistry
80. A Metabolic Basis for Alzheimer Disease
    George L. Perry, Akihiko Nunomura, Arun K. Raina, Gjumrakch M. Aliev, Sandra L. Siedlak, Peggy L.R. Harris, Gemma Casadesús, Robert B. Petersen, William Z. Bligh-Glover, Elizabeth K. Balraj et al. · 2003 · Neurochemical Research
81. PPARγ agonists as new therapeutic agents for the treatment of Alzheimer's disease
    Gary E. Landreth · 2006 · Experimental Neurology
82. Phenserine
    Jochen Klein · 2007 · Expert Opinion on Investigational Drugs
83. Pharmacotherapy of Alzheimer Disease
    Dennis Chuen Chai Seow, Serge G. Gauthier · 2007 · The Canadian Journal of Psychiatry
84. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis
    Gary L. Wenk, Wojciech Danysz, Daschelle Roice · 1996 · Neuroreport
85. Return to the RNAi World: Rethinking Gene Expression and Evolution (Nobel Lecture)
    Craig C. Mello · 2007 · Angewandte Chemie International Edition
86. Quantitative Magnetization Transfer Imaging in Alzheimer Disease
    Basil H. Ridha, Daniel J. Tozer, Mark R. Symms, Katherine C. Stockton, Emma B Lewis, Musib M. Siddique, David G. MacManus, Martin N. Rossor, Nick C. Fox, Paul S. Tofts · 2007 · Radiology
87. Progress in the Discovery of BACE Inhibitors
    Lorin A. Thompson, Joanne J. Bronson, F. Christopher Zusi · 2005 · Current Pharmaceutical Design
88. M1 Muscarinic Agonists Target Major Hallmarks of Alzheimers Disease – an Update
    Abraham Fisher · 2007 · Current Alzheimer Research
89. Basement membranes, microfibrils and β amyloid fibrillogenesis in Alzheimer's disease: high resolution ultrastructural findings
    Sadayuki Inoué, Mie Kuroiwa, Robert Kisilevsky · 1999 · Brain Research Reviews
90. Harnessing Functional Plasticity of Enzymes: A Fluorogenic Probe for Imaging 17β-HSD10 Dehydrogenase, an Enzyme Involved in Alzheimer's and Parkinson's Diseases
    Mary K. Froemming, Dalibor Sameš · 2007 · Journal of the American Chemical Society
91. γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
    Ian Churcher, Dirk Beher · 2005 · Current Pharmaceutical Design
92. The structure of microtubule motor proteins
    Alexander Marx, J. Müller, Eckhard Mandelkow� · 2005 · Advances in protein chemistry
93. New protein kinase C activator regulates amyloid precursor protein processing in vitro by increasing α‐secretase activity
    Hongqi Yang, Jing Pan, Maowen Ba, Zhikun Sun, Guozhao Ma, Guoqiang Lü, Qin Xiao, Shengdi Chen · 2007 · European Journal of Neuroscience
94. What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease?
    Mark A. Smith, George Perry · 1998 · Journal of Chemical Neuroanatomy
95. Pharmacology of Aniracetam
    James R. Martin, Willy E. Haefely · 1993 · Clinical Drug Investigation
96. The secretases of Alzheimer's disease
    Michael S. Wolfe · 2003 · Current topics in developmental biology/Current Topics in Developmental Biology
97. Immunotherapy as treatment for Alzheimer’s disease
    Cheryl A. Hawkes, JoAnne McLaurin · 2007 · Expert Review of Neurotherapeutics
98. Prospective neuropsychological assessment of nondemented patients with biopsy proven senile plaques
    Ian R. Mackenzie, Richard S. McLachlan, Cynthia S. Kubu, Laurie A. Miller · 1996 · Neurology
99. A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer’s disease
    Frederick A. Schmitt, Melody Ann Ryan, Gregory E. Cooper · 2007 · Expert Opinion on Drug Metabolism & Toxicology
100. Therapeutic Treatment of Alzheimers Disease Using Metal Complexing Agents
     Katherine Ann Price, Peter John Crouch, Anthony Robert White · 2007 · Recent Patents on CNS Drug Discovery
101. Insulysin: An Allosteric Enzyme As a Target for Alzheimer's Disease
     Eun Suk Song, Louis B. Hersh · 2005 · Journal of Molecular Neuroscience
102. A Two Decade Contribution of Molecular Cell Biology to the Centennial of Alzheimer's Disease: Are We Progressing Toward Therapy?
     Katleen Dillen, Wim G. Annaert · 2006 · International review of cytology
103. Comparative evolutionary genomics of the HADH2 gene encoding Aβ-binding alcohol dehydrogenase/17β-hydroxysteroid dehydrogenase type 10 (ABAD/HSD10)
     Alexandra T. Marques, Agostinho Antunes, Pedro Alexandrino Fernandes, Maria João Ramos · 2006 · BMC Genomics
104. Serum amyloid P component induces neuronal apoptosis and beta-amyloid immunoreactivity.
     Z. Urbányi, L. Laszlo, T. Tomasi, E. Tóth, Éva Mekes, M. Sass, T. Pázmány · 2003 · Brain Research
105. Structural and Functional Neuroimaging in Alzheimers Disease: An Update
     Alison C. Burggren, Susan Y. Bookheimer · 2002 · Current Topics in Medicinal Chemistry
106. Serum amyloid P component induces TUNEL-positive nuclei in rat brain after intrahippocampal administration
     Zoltán Urbányi, Miklós Sass, Judit Laszy, Viktor Takács, István Gyertyán, Tamás Pázmány · 2007 · Brain Research
107. Basement membrane and β amyloid fibrillogenesis in Alzheimer's disease
     Sadayuki Inoué · 2001 · International review of cytology
108. Zurück zur RNAi‐Welt: Gedanken zur Genexpression und Evolution (Nobel‐Vortrag)
     Craig C. Mello · 2007 · Angewandte Chemie
109. Localization of Human Serum Amyloid P Component and Heparan Sulfate Proteoglycan in In Vitro‐Formed Aβ Fibrils
     Holm Nielsen, Nybo, Junker, Toftedal Hansen, Rasmussen, Svehag · 2000 · Scandinavian Journal of Immunology
110. Association of minimal thickness of the medial temporal lobe with hippocampal volume, maximal and minimal hippocampal length: Volumetric approach with horizontal magnetic resonance imaging scans for evaluation of a diagnostic marker for neuroimaging of Alzheimer’s disease
     千草 魚谷, Kaoru Sugimori, Katsuji Kobayashi · 2006 · Psychiatry and Clinical Neurosciences
111. Immunotherapy for Alzheimer's Disease and Other Dementias
     Delphine Boche, James A. R. Nicoll, Roy O. Weller · 2006 · Clinical Neuropharmacology
112. Basement Membrane and β‐Amyloid Fibrillogenesis in Alzheimer′s Disease.
     Sadayuki Inoué · 2002 · ChemInform